Be the first person to write a business review for PRA International

Prana Biotechnology Limited (Prana) is a development-stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.

Premier Research Group, Ltd. was founded in 2002 and is based in Wokingham, United Kingdom. Premier Research Group, Ltd., a contract research organization, provides clinical trial management and information services to the pharmaceutical and biotechnology industries in Europe, Asia, Africa, Australia, Latin America, and North America. The company focuses its research and development program on enhancing software systems used to support its clinical trials management and information services. Its services include dedicated clinical sites, medical and safety management, medical writing, data management, biostatistics, interactive voice response systems, regulatory affairs, and quality assurance. The company conducts its clinical research in the areas of infectious diseases, oncology, pediatrics, analgesia, and CNS. The company was formerly known as CRC Development Limited and changed its name to Premier Research Group, Ltd. in November, 2004.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

Promega helps researchers plumb the depths of the life sciences. The company sells more than 2,000 products that allow scientists to conduct various experiments in gene, protein, and cellular research. Its reagents and other goods fall into more than two dozen categories, including DNA and RNA purification, genotype analysis, protein expression and analysis, and DNA sequencing. Promega has branches in about a dozen countries around the world. The firm sells its products directly and through more than 50 distributors. Customers include academic, pharmaceutical, and clinical labs, as well as government agencies and energy and chemical companies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.